<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nielsen SW</submitter><funding>NEYE Foundation</funding><pagination>1862</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8999713</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(7)</volume><pubmed_abstract>(1) The study evaluated correlations between multi-frequency vibrometry (MF-V) and the measure of chemotherapy-induced peripheral neuropathy developed by the European Organization for the Research and Treatment of Cancer (CIPN18). (2) Patients with cancer scheduled to undergo treatment with capecitabine and oxaliplatin (CAPOX) or carboplatin and paclitaxel (Carbo-Tax) were recruited in a prospective, observational study with MF-V and the CIPN18 from baseline to one year after end of treatment. (3) The study recruited 31 evaluable patients. All MF-V measurements correlated significantly with the CIPN18 scores (r = 0.25−0.48, p > 0.003), with a low frequency (32 Hz) from metatarsals showing the best correlation coefficients (0.059 Z-score per CIPN18 point change, r = 0.48, CI-95 = [0.32; 0.6</pubmed_abstract><journal>Journal of clinical medicine</journal><pubmed_title>Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes.</pubmed_title><pmcid>PMC8999713</pmcid><funding_grant_id>N/a</funding_grant_id><pubmed_authors>Lindberg S</pubmed_authors><pubmed_authors>Nielsen SW</pubmed_authors><pubmed_authors>Eckhoff L</pubmed_authors><pubmed_authors>Ruhlmann CHB</pubmed_authors><pubmed_authors>Herrstedt J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes.</name><description>(1) The study evaluated correlations between multi-frequency vibrometry (MF-V) and the measure of chemotherapy-induced peripheral neuropathy developed by the European Organization for the Research and Treatment of Cancer (CIPN18). (2) Patients with cancer scheduled to undergo treatment with capecitabine and oxaliplatin (CAPOX) or carboplatin and paclitaxel (Carbo-Tax) were recruited in a prospective, observational study with MF-V and the CIPN18 from baseline to one year after end of treatment. (3) The study recruited 31 evaluable patients. All MF-V measurements correlated significantly with the CIPN18 scores (r = 0.25−0.48, p > 0.003), with a low frequency (32 Hz) from metatarsals showing the best correlation coefficients (0.059 Z-score per CIPN18 point change, r = 0.48, CI-95 = [0.32; 0.6</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2026-06-18T03:10:11.413Z</modification><creation>2025-04-04T22:12:08.262Z</creation></dates><accession>S-EPMC8999713</accession><cross_references><pubmed>35407470</pubmed><doi>10.3390/jcm11071862</doi></cross_references></HashMap>